Eyenovia (EYEN) Competitors $2.67 -0.70 (-20.77%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$2.63 -0.04 (-1.50%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYEN vs. ASBP, LGVN, ELEV, MTEX, LPCN, JATT, LEXX, CING, COCP, and DRRXShould you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Aspire Biopharma (ASBP), Longeveron (LGVN), Elevation Oncology (ELEV), Mannatech (MTEX), Lipocine (LPCN), JATT Acquisition (JATT), Lexaria Bioscience (LEXX), Cingulate (CING), Cocrystal Pharma (COCP), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Eyenovia vs. Its Competitors Aspire Biopharma Longeveron Elevation Oncology Mannatech Lipocine JATT Acquisition Lexaria Bioscience Cingulate Cocrystal Pharma DURECT Aspire Biopharma (NASDAQ:ASBP) and Eyenovia (NASDAQ:EYEN) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Does the media favor ASBP or EYEN? In the previous week, Aspire Biopharma and Aspire Biopharma both had 2 articles in the media. Aspire Biopharma's average media sentiment score of 0.62 beat Eyenovia's score of 0.44 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Overall Sentiment Aspire Biopharma Positive Eyenovia Neutral Which has higher earnings and valuation, ASBP or EYEN? Aspire Biopharma has higher earnings, but lower revenue than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAspire BiopharmaN/AN/AN/AN/AN/AEyenovia$67.06K114.78-$27.26M-$58.40-0.05 Which has more risk and volatility, ASBP or EYEN? Aspire Biopharma has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Do institutionals and insiders hold more shares of ASBP or EYEN? 19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 48.0% of Aspire Biopharma shares are held by insiders. Comparatively, 7.1% of Eyenovia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ASBP or EYEN? Eyenovia received 174 more outperform votes than Aspire Biopharma when rated by MarketBeat users. Likewise, 64.21% of users gave Eyenovia an outperform vote while only 0.00% of users gave Aspire Biopharma an outperform vote. CompanyUnderperformOutperformAspire BiopharmaOutperform VotesNo VotesUnderperform Votes1100.00% EyenoviaOutperform Votes17464.21% Underperform Votes9735.79% Is ASBP or EYEN more profitable? Aspire Biopharma has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. Aspire Biopharma's return on equity of 0.00% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets Aspire BiopharmaN/A N/A N/A Eyenovia -114,639.41%-1,108.24%-139.36% Do analysts recommend ASBP or EYEN? Eyenovia has a consensus target price of $2.00, indicating a potential downside of 25.09%. Given Eyenovia's stronger consensus rating and higher possible upside, analysts plainly believe Eyenovia is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryEyenovia beats Aspire Biopharma on 7 of the 12 factors compared between the two stocks. Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYEN vs. The Competition Export to ExcelMetricEyenoviaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.70M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.058.6727.1419.96Price / Sales114.78262.53416.10157.63Price / CashN/A65.8538.2534.64Price / Book0.166.597.074.69Net Income-$27.26M$143.75M$3.23B$248.14M7 Day Performance-45.29%0.68%0.71%0.91%1 Month Performance132.15%11.93%9.65%5.71%1 Year Performance-94.64%4.33%32.07%14.71% Eyenovia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYENEyenovia0.4861 of 5 stars$2.67-20.8%$2.00-25.1%-94.9%$7.70M$67.06K-0.0540Positive NewsShort Interest ↑ASBPAspire BiopharmaN/A$0.39-10.5%N/AN/A$19.07MN/A0.00N/ANews CoverageGap DownLGVNLongeveron3.5443 of 5 stars$1.25+0.8%$8.67+593.3%-27.1%$18.66M$2.23M-0.2020Gap DownELEVElevation Oncology3.4138 of 5 stars$0.31+3.7%$3.39+987.6%-88.7%$18.44MN/A-0.3840Trending NewsAnalyst ForecastShort Interest ↓Analyst RevisionMTEXMannatech1.4665 of 5 stars$9.37-1.5%N/A+19.5%$17.81M$115.04M-11.57250Positive NewsShort Interest ↓LPCNLipocine2.3339 of 5 stars$3.28-3.0%$9.00+174.4%-60.3%$17.55M$3.67M-4.3210News CoverageAnalyst ForecastAnalyst RevisionJATTJATT AcquisitionN/A$1.01-1.0%N/A-67.1%$17.42MN/A0.003High Trading VolumeLEXXLexaria Bioscience2.5578 of 5 stars$0.98-4.2%$7.00+616.4%-68.5%$17.16M$525.92K-1.957News CoveragePositive NewsCINGCingulate1.9726 of 5 stars$3.98+1.5%$26.00+553.3%+535.7%$16.90MN/A-0.4720Short Interest ↑Gap DownCOCPCocrystal Pharma2.6812 of 5 stars$1.65-3.5%$7.00+324.2%-45.0%$16.78MN/A-0.8910Short Interest ↑DRRXDURECT1.3775 of 5 stars$0.53+0.3%N/A-59.0%$16.55M$1.86M-0.8780Positive News Related Companies and Tools Related Companies ASBP Competitors LGVN Competitors ELEV Competitors MTEX Competitors LPCN Competitors JATT Competitors LEXX Competitors CING Competitors COCP Competitors DRRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYEN) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
